---
title: "VK2735 in Chronic weight management: Pharmacokinetics"
description: "Formulary evidence on VK2735 in Chronic weight management: Pharmacokinetics. Topics: Subcutaneous formulation: half-life and time to maximum concentration after single doses, Subcutaneous formulation: phase 1 pharmacokinetic summary in the sponsor presentation, Subcutaneous formulation: predictability of pharmacokinetics in the phase 1 single ascending dose study, Subcutaneous formulation: pharmacokinetic parameters at 5.0 mg weekly in the phase 2 trial, and 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Subcutaneous formulation: half-life and time to maximum concentration after single doses

> “Following single subcutaneous doses, VK2735 demonstrated a half-life of approximately 170 to 250 hours, a Tmax (time to reach maximum plasma concentration) ranging from approximately 75 to 90 hours, and excellent therapeutic exposures.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-2.1.2.6.3-2"></a>

### Subcutaneous formulation: phase 1 pharmacokinetic summary in the sponsor presentation

> “Tmax ~72 hours, gradual onset; T1/2 170 – 253 hours, amenable to weekly dosing”
> “Excellent exposures from weekly dosing suggests less frequent dosing a possibility”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.6.3-3"></a>

### Subcutaneous formulation: predictability of pharmacokinetics in the phase 1 single ascending dose study

> “In the SAD portion of the study, VK2735 demonstrated promising safety and tolerability, as well as a predictable pharmacokinetic (PK) profile.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-2.1.2.6.3-4"></a>

### Subcutaneous formulation: pharmacokinetic parameters at 5.0 mg weekly in the phase 2 trial

| Dose | Cmax (ng/mL) | AUC0-168 (ng*h/mL) | T1/2 (h) |
| --- | --- | --- | --- |
| VK2735 5.0 mg | “1,120” | “158,000” | “171” |

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

<a id="topic-2.1.2.6.3-5"></a>

### Subcutaneous formulation: plasma levels after the last dose and the rationale for monthly dosing

> “PK, exposure profile suggests monthly dosing may be feasible”

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

> “An evaluation of plasma levels of VK2735 at various timepoints following the 13-week study was also conducted. The company believes the results support the feasibility of once-monthly dosing in the maintenance setting.”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.6.3-6"></a>

### Subcutaneous formulation: half-life cited for every-other-week and monthly maintenance regimens

> “We designed this study so that the compound has a pretty long half-life. It's 8- 10 days or so half-life. If you think of a dosing regimen being preferably every four to five half-lives, it raised the possibility early on that maybe we could dose monthly and reduce the frequency of injections.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

> “This supports the company's view that VK2735's differentiated PK profile, with an extended half-life and excellent long-term exposures, may provide for greater flexibility in dosing compared with existing options.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.6.3-7"></a>

### Subcutaneous formulation: preclinical pharmacokinetics compared with tirzepatide in primates

> “PK profile demonstrates higher Cmax, later Tmax, longer T1/2 vs. tirzepatide”
> “Differences lead to increased exposures over time”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.6.3-8"></a>

### Oral formulation: plasma exposure in preclinical models

> “We developed an oral tablet formulation that demonstrated encouraging plasma exposures in model studies.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.3-9"></a>

### Oral formulation: dose proportionality of exposure in the phase 1 multiple ascending dose study

> “Plasma exposures increase predictably through 100 mg dose level”
> “Figure 6. Oral exposures demonstrate linearity with increasing dose.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.3-10"></a>

### Oral formulation: bioavailability, half-life, and food effect

No evidence found.

<a id="topic-2.1.2.6.3-11"></a>

### Distribution, metabolism, and elimination pathways

No evidence found.

Additional sources: [Lian et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1002/oby.23938)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
